Fycompa
Malignant Glioma
Mayo ClinicPhase 4 / ApprovedDormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 81/ 100
Competitive context
109 Active assets in the Malignant Glioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Kailin Yang, MD, PhD | Phase 2 | BB |
Marizomib Aadi Bioscience, Inc. | Phase 2 | BB |
Valproic Acid Virginia Commonwealth University | Phase 2 | BB |
Valaciclovir Trogenix ltd | Phase 2 | BB |
DISODIUM 4-((TERT-BUTYLIMINO)METHYL)BENZENE-1,3-DISULFONATE N-OXIDE Oblato, Inc. | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Fycompa is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →